Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Tolerability of Hair Stimulating Complex (HSC) in Female Pattern Hair Loss

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03662854
Recruitment Status : Active, not recruiting
First Posted : September 10, 2018
Last Update Posted : February 21, 2019
Sponsor:
Information provided by (Responsible Party):
Histogen

Brief Summary:
This double-blind placebo-controlled study will assess the tolerability, feasibility, and pharmacodynamics of intradermal Hair Stimulating Complex (HSC) in up to 18 of 27 women with Ludwig 1 or 2 classification or the Savin Frontal classification of hair loss. Safety measures include vital signs, dermatological examination of the scalp, pre- and post-dose blood and urine collection, as well as Investigator Global Assessments and subject self assessments throughout the 22-week study.

Condition or disease Intervention/treatment Phase
Alopecia Biological: Hair Stimulating Complex (HSC) Other: Phosphate Buffered Saline Phase 1

Detailed Description:
The study is a double-blind, placebo-controlled, randomized single site trial. The study is to be conducted in La Jolla, CA and is primarily designed to evaluate safety in the clinical application of injected HSC by assessing the tolerability of HSC, as well as the volume that can be delivered safely in the intradermal region of the scalp using a syringe with 31-gauge 1.75 mm length needle. The main study (18 weeks) involves the two treatment time points, collection of lab samples (blood/urine) for screening, and before and after the two treatment time points. Six of the seven total visits (including screening) in the study are conducted in the first 18 weeks. The final visit is for investigator monitoring, global photographs and final lab collection 30 days after the 18-week evaluation point. A 2 year follow up questionnaire will be sent to the patient to collect additional safety information. Additional dermatological exam of the scalp, as well as Subject and Investigator Assessments will also be assessed. The secondary goal of the study will be to explore whether an efficacy signal of the change in hair growth can be detected using an independent panel of physician's comparing global photographs taken at baseline to week 18 (and baseline to week 22), for changes.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Placebo-controlled study
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double-blinding
Primary Purpose: Treatment
Official Title: Phase 1, Randomized, Double-Blind, Vehicle-Controlled Study of Safety and Tolerability of Hair Stimulating Complex (HSC) in Female Subjects With Female Pattern Hair Loss
Actual Study Start Date : July 2, 2018
Actual Primary Completion Date : January 21, 2019
Estimated Study Completion Date : January 21, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Hair Stimulating Complex
Hair Stimulating Complex (HSC) is derivative of hypoxia-induced multipotent cell conditioned media enriched for certain key growth factors
Biological: Hair Stimulating Complex (HSC)
Patients will receive 2 mL of HSC separated by 6 weeks (total of 4 mL of HSC)

Placebo Comparator: Phosphate Buffered Saline
Phosphate Buffered Saline
Other: Phosphate Buffered Saline
Patients will receive 2 mL of Phosphate Buffered Saline separated by 6 weeks (total of 4 mL of Phosphate Buffered Saline)




Primary Outcome Measures :
  1. Number of Adverse Events due to HSC [ Time Frame: Continuous for 22 weeks after first dose ]
    Safety and tolerability of HSC by comparing adverse events to baseline


Secondary Outcome Measures :
  1. Investigator Assessments of Global Photographs compared to baseline [ Time Frame: Day 1, Week 18 and 22 ]
    Investigator Assessments of Global Photographs compared to baseline



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Female, 40-70 years of age.
  • A healthy scalp with no cutaneous disorder.
  • Good general health.
  • Must fulfill the Ludwig I or II classification or Savin classification of frontal hair loss (see Appendix 1).
  • Willing and able to comply with scheduled visits (6 visits in 22 weeks).
  • Willing to maintain the same hair style and color during the study period.
  • Subjects not already using any over-the-counter or prescription hair/scalp treatments, must be willing to refrain from starting use of any new hair/scalp products other than the provided study product for the duration of the study.
  • Willingness to have blood and urine samples taken before and after each of the two treatments to evaluate overall systemic effect and also at Weeks 18 and 22. Also willing to give additional serum samples at each collection for long-term storage and immunogenicity testing by Histogen to components in HSC.
  • Be able to speak and read English to the standard required to provide written informed consent and to cooperate with the study staff.
  • Female subjects will be either of non-childbearing potential defined as:

    1. Having no uterus
    2. No menses for at least 12 months. Or; (WOCBP) women of childbearing potential must agree to use an effective method of birth control during the course of the study, such as:
    1. Oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device
    2. Intrauterine coil
    3. Bilateral tubal ligation
    4. Barrier method used with an additional form of contraception (e.g., sponge, spermicide or condom)
    5. Abstinence (If practicing abstinence must agree to use barrier method described above (4) if becomes sexually active).
    6. Vasectomized partner (Must agree to use barrier method described above (4) if becomes sexually active with non-vasectomized).

      -

      Exclusion Criteria:

  • Known sensitivity to any of the test material ingredients.
  • History of keloid formation or hyperpigmentation.
  • Pregnant, planning pregnancy or breastfeeding during the course of the study.
  • A history of any acute or chronic illness that in the opinion of the investigators might confound the results of the study including some drugs or medications.
  • Active skin diseases (e.g. Eczema, seborrheic dermatitis, psoriasis, skin cancer, sun damaged skin with actinic keratosis on scalp, excessive number and size of seborrheic keratosis, etc.).
  • Routine high dosage use of anti-inflammatory medications (aspirin, ibuprofen, corticosteroids), immunosuppressive drugs or antihistamine medications (Note that steroid nasal spray / drops and/or topical steroids administered to the eye(s) are not exclusion criteria, and that a daily dose of 81 - 325mg aspirin is also permitted).
  • (Auto-) Immunological disorders such as HIV positive, alopecia areata, and systemic lupus erythematosus.
  • Participation in any clinical study within one month prior to enrollment or planned participation in any clinical trial during the duration of their participation in this study.
  • Treatment with an experimental or investigative drug or product within the last 3 months.
  • Moderate/severe Seborrheic dermatitis (scalp).
  • Damaged skin in or around test sites (including sunburn, uneven skin tones, tattoos, scars or other disfiguration of the test site).
  • Use of any over-the-counter or prescription hair/scalp treatments for less than 6 months from date subject would start study, including finasteride or minoxidil.
  • Discontinuation of the use of an over-the-counter or prescription hair/scalp treatments within the last 6 months
  • Use of laser or light device for the scalp for purposes of hair growth within the last 6 months or any plans to use these devices during the duration of the study.
  • History of hair transplantation surgery during the last 6 months.
  • Currently using hair system or wig and/or unwilling to refrain from use throughout the duration of the study.
  • History of malignancy, other than non-melanoma skin cancer. Any condition for which the Investigator determines that the subject could be placed under undue hazard.
  • Known allergy to rice.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03662854


Locations
Layout table for location information
United States, California
Cosmetic Laser Dermatology
San Diego, California, United States, 92121
Sponsors and Collaborators
Histogen
Layout table for additonal information
Responsible Party: Histogen
ClinicalTrials.gov Identifier: NCT03662854    
Other Study ID Numbers: 16-HIS002-US
First Posted: September 10, 2018    Key Record Dates
Last Update Posted: February 21, 2019
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alopecia
Hypotrichosis
Hair Diseases
Skin Diseases
Pathological Conditions, Anatomical